Mizuho raises Sage Therapeutics target to $9 on Biogen bid
Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...
pharmaphorum23h
Sage takes another hit as Alzheimer's drug is canned
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the plug on the drug in Parkinson's disease. The decision, prompted by a ...
BioSpace10h
Inhibikase Scraps Parkinson’s Drug After Disappointing Mid-Stage Data
Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...